Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06452758
Other study ID # REDs2024
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 20, 2024
Est. completion date June 30, 2024

Study information

Verified date June 2024
Source Poznan University of Physical Education
Contact Hanna Dziewiecka, Msc
Phone 606880282
Email hannadziewiecka@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to learn about relative energy deficiency in male and female rowers at the end of the direct sport preparation phase of the annual training cycle. The main questions: - How will energy intake influence leptin, cortisol levels, mood, gut discomfort, and permeability? The observational study involves male and female rowers from the Polish rowing team. Participants will perform 2000 meter ergometer test and 6000 ergometer test in annual training cycle. Researchers will compare outcomes from both tests.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date June 30, 2024
Est. primary completion date June 26, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 23 Years
Eligibility Inclusion Criteria: - Membership in Polish Rowing Team, - minimum five years of training, - total training time minimum of 240 minutes, - filling out a food diary, - finishing 2000-meter ergometer test. Exclusion Criteria: - Probiotics within the last three months, - prebiotics within the last three months - antibiotic therapy within the last three months, - dietary regime, - gastrointestinal diseases.

Study Design


Intervention

Other:
2000 meter ergometer test
Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.

Locations

Country Name City State
Poland Poznan University of Physical Education, Faculty of Sport Sciences in Gorzow Gorzów Wielkopolski Lubuskie

Sponsors (1)

Lead Sponsor Collaborator
Poznan University of Physical Education

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary -FABP (intestinal fatty acid binding protein)to measure epithelial wall injury I-FABP concentration measured in blood [ng/ml] using commercially availableenzyme-linked immunosorbent assays Blood samples was taken from the cubital vein at three-time points: before each stress test (after overnight fasting) up to one hour after getting up, 1 minute after the test, and 3-hour recovery period
Primary Leptin to measure long-term energy balance Leptin concentration measured in blood [ng/ml] using commercially availableenzyme-linked immunosorbent assays Blood samples was taken from the cubital vein at three-time points: before each stress test (after overnight fasting) up to one hour after getting up, 1 minute after the test, and 3-hour recovery period
Primary Cortisol to measure stress Stress hormone concentration measured in blood [ng/ml] using commercially available enzyme-linked immunosorbent assays Blood samples was taken from the cubital vein at three-time points: before each stress test (after overnight fasting) up to one hour after getting up, 1 minute after the test, and 3-hour recovery period
Primary sCD14 multifunctional lipopolysaccharide receptor sCD14 concentration measured in blood [ug/ml] using commercially available enzyme-linked immunosorbent assays Blood samples was taken from the cubital vein at three-time points: before each stress test (after overnight fasting) up to one hour after getting up, 1 minute after the test, and 3-hour recovery period
Primary Claudin to measure tight junction leakage Claudin concentration measured in blood [ng/ml] using commercially available enzyme-linked immunosorbent assays Blood samples was taken from the cubital vein at three-time points: before each stress test (after overnight fasting) up to one hour after getting up, 1 minute after the test, and 3-hour recovery period
Primary POMS Profile of Mood States day before the test
Primary REST-Q sport Recovery-Stress questionnaire for Athletes day before the test
Secondary energy energy [kcal ]of food intake measured by food diary Time Frame: whole day (24hours) before test, in the morning before the test
Secondary protein protein [g ]of food intake measured by food diary Time Frame: whole day (24hours) before test, in the morning before the test
Secondary fat fat [g ]of food intake measured by food diary Time Frame: whole day (24hours) before test, in the morning before the test
Secondary carbohydrate carbohydrate [g ]of food intake measured by food diary Time Frame: whole day (24hours) before test, in the morning before the test
Secondary fiber fiber [g ]of food intake measured by food diary Time Frame: whole day (24hours) before test, in the morning before the test
Secondary Body mass Body mass [kg] measured by electronic scale to the nearest 0,05 kg (Tanita BC 418 MA Tanita Corporation, Tokyo, Japan) in the morning before the test up to 1 hour after getting up
Secondary Body fat Body fat [%] measured by electronic scale (Tanita BC 418 MA Tanita Corporation, Tokyo, Japan) in the morning before the test up to 1 hour after getting up
Secondary Total body water Body water [%] measured by electronic scale (Tanita BC 418 MA Tanita Corporation, Tokyo, Japan) in the morning before the test up to 1 hour after getting up
Secondary Lean body mass Lean body mass [kg] measured by electronic scale (Tanita BC 418 MA Tanita Corporation, Tokyo, Japan) in the morning before the test up to 1 hour after getting up
Secondary Height [cm] measured by high meter in the morning before the test up to 1 hour after getting up
Secondary Self reported scale of gastrointestinal symptoms e.g.burping, heartburn, flatulence, abdominal pain, the urge to reiterate, vomiting, diarrhoea, nausea, dizziness, and stitch 10-point scale where 10 was the symptom with the greatest severity up to 1 hours after the test
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT04156711 - Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2
Completed NCT05872139 - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging N/A
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02334839 - The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction N/A
Recruiting NCT02020044 - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) N/A
Completed NCT01691404 - Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Terminated NCT01412216 - The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance Phase 2
Completed NCT01319344 - Effect of Eplerenone on Endothelial Function in Metabolic Syndrome Phase 3
Completed NCT00990730 - Atherosclerosis in Rheumatoid Arthritis N/A
Completed NCT00848302 - Endothelial Function in Human Arteries Early Phase 1
Completed NCT00987974 - Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury Phase 4
Completed NCT00532844 - A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction Phase 2
Completed NCT00376246 - Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects Phase 4
Completed NCT00775099 - Combustion Derived Air Pollution and Vascular Function N/A